Leap Therapeutics

Leap Therapeutics is a clinical-stage biopharmaceutical company focused on acquiring and developing novel therapies at the forefront of cancer research. The company's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being tested in clinical trials involving patients with esophageal, gastric, colorectal, gynecological, and prostate cancers. Leap Therapeutics has entered into a strategic collaboration with BeiGene to gain rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.